Presentations

Read research from Cogstate scientists as presented at industry conferences.

Validity of a remote supervised Preclinical Alzheimer’s Disease Cognitive Composite (PACC) score in preclinical and prodromal Alzheimer’s disease

Presented at AAIC 2022

Neuropsychological tests administered to individuals in locations different from the assessor (i.e., remote assessment) can provide substantial reductions in patient burden, study cost and barriers to access. However, such tests must be optimized and validated for use in remote settings. The preclinical cognitive composite score (PACC) is derived from neuropsychological tests of episodic memory, complex attention, and general mental status and has been validated as an outcome for use in clinical trials of preclinical Alzheimer’s disease (AD) . This study determined whether a set of neuropsychological tests of these domains, can provide a valid and reliable digital PACC score in individuals with early AD, when given in a remote context.

View Poster

User-led Design of a Self-administered Smartphone-based Learning and Memory Assessment

Presented at AAIC 2022

The International Shopping List test (ISLT) is a verbal word list learning assessment set within a realistic shopping list context, supporting ease of cultural adaptation, and addressing content validity and patient relevance. Improvements to and the wide adoption of natural language processing (NLP) software has enabled the possibility for self-administered tests of verbal learning. A beta version of a self-administered, smartphone-application (app) was developed, using the virtual assistant and NLP: the “List Learning and Memory Assessment (Lila™)”.

View Poster

Rater Perspectives on Applied Training of Cognitive Clinical Outcome Assessments

Presented at AAIC 2022

Cognitive assessments are critical in understanding the effects of investigational therapies. Their use can be vulnerable to variability in test administration and scoring. Careful training of raters on proper test administration cognitive tests is crucial to ensure optimal reliability and validity of clinical outcome data. Trainee feedback is important in ensuring a training program is comprehensive, well-delivered and well-received.

View Poster

Detection of Mild Cognitive Impairment Using In-clinic and Remote Unsupervised Digital Cognitive Assessments

Presented at AAIC 2022

The Cogstate Brief Battery (CBB) is a digital cognitive assessment validated for Alzheimer’s disease (AD) and unsupervised use. The CBB assesses processing speed, attention, visual learning, and working memory and was offered to cognitively normal (CN) and mild cognitive impairment (MCI) participants in ADNI-3.

View Poster

Leveraging Remote Assessments and Central Raters to Optimize Data Quality in Rare Neurodevelopmental Disorders

Presented at the European Conference on Rare Disease 2022

Fully remote or hybrid administration of clinical outcome measures in rare neurodevelopmental disorders trials is increased due to the ongoing pandemic and recognition that remote assessments reduce burden on families. Many assessments in rare neurodevelopmental disorders trials are complex. Remote/hybrid trials readily allow for the use of centralized raters to administer/score scales. This poster explores the data quality impact of leveraging centralized raters.

View Poster

Validity and reliability of a composite cognitive outcome measure for clinical trials in dementia with Lewy bodies

Presented at AD/PD 2022

Both the FDA and a number of industry bodies including the International Society for Pharmacoeconomics and Outcomes Research ‘ISPOR’ place considerable emphasis on patient focused drug development and have sought to develop guidance and good practice that ensures patient centricity. PerfO assessments may be particularly valuable sources of information regarding treatment benefit where patient populations have substantial difficulty in providing reliable self-report and/or where concepts of interest for measurement are difficult to observe, or impractical or difficult to measure. This is particularly the case for dementia and other diseases and conditions where cognitive impairment is a prominent feature.

View Presentation

Disease specific global clinical rating scales for Lewy-body dementia: early concept identification

Presented at AD/PD 2022

In several areas of clinical research, expert groups have sought to develop global instruments which are disease specific. Discussions are underway to develop such a tool for Dementia with Lewy Bodies (DLB). An initial component of this research is understanding the signs and symptoms considered important in a global assessment of the severity of DLB. Data consolidated here come from literature reviews and exploration of reported clinical trial designs. The most frequently used COAs were the CDR, NPI, and MMSE, suggesting a comprehensive and relevant global DLB instrument should include a range of motor, cognitive, neuropsychiatric, and functional domains.

View Poster

Monthly at-home computerized cognitive testing to detect diminished practice effects in preclinical Alzheimer’s disease

Presented at CTAD 2021

A major challenge for Alzheimer’s disease (AD) secondary prevention trials is the long and subtle course of cognitive decline observed in individuals with preclinical AD. Computerized testing has the potential to capture subtle cognitive change more rapidly, by enabling standardized administration and data analyses allowing for remote, unsupervised, and more frequent assessments. The higher frequency assessments afforded through the use of computerized testing enable the study of practice effects (PE) that can occur with repeated assessments in older adults, and which previously has been shown to provide a meaningful cognitive marker in preclinical AD.

View Poster

Rater Academy: Increasing efficiency in training clinicians within Rare Disease trials

Presented at NORD 2021

Clinicians participating in Rare Disease clinical trials range in their level of experience with specific outcome measures. Some measures require an advanced degree and some are completed by junior staff. The Vineland Adaptive Behavior Scale, Third Edition (Vineland-3) is a caregiver interview commonly used in Rare Disease trials, specifically developmental disabilities trials.

View Poster

CBB in ADNI-3 Valid In-Clinic and At-Home

Presented at AD/PD 2021

Recent data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) show the Cogstate Brief Battery (CBB) to be valid and sensitive for in-clinic and at-home assessment in both cognitively normal and MCI populations. ADNI is a landmark longitudinal multicenter study designed to develop biomarkers for the early detection of AD. In this video, Dr. Chris Edgar recaps his AD/PD presentation, which discusses the data collected during ADNI-3 demonstrating known-groups validity, equivalence between in-clinic and at-home assessment, and longitudinal sensitivity of the CBB.

Watch the Video

How can we help you optimize the measurement of brain health?

Please fill out the form to get in touch